Graft Dysfunction Clinical Trials

8 recruitingLast updated: May 13, 2026

There are 8 actively recruiting graft dysfunction clinical trials across 4 countries. Studies span Phase 2, Phase 1. Top locations include Philadelphia, Pennsylvania, United States, San Francisco, California, United States, Montreal, Quebec, Canada. Updated daily from ClinicalTrials.gov.


Graft Dysfunction Trials at a Glance

8 actively recruiting trials for graft dysfunction are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Philadelphia, San Francisco, and Montreal. Lead sponsors running graft dysfunction studies include University of Pennsylvania, Sean Fain, and Lund University Hospital.

Browse graft dysfunction trials by phase

Treatments under study

About Graft Dysfunction Clinical Trials

Looking for clinical trials for Graft Dysfunction? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Graft Dysfunction trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Graft Dysfunction clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

Bronchiolitis Obliterans SyndromeLung transplantationChronic lung allograft dysfunction
Steven Hays, MD30 enrolled1 locationNCT06018766
Recruiting
Phase 2

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

Acute Lung Injury(ALI)Natural Killer Cell Mediated ImmunityPrimary Graft Dysfunction+1 more
University of California, San Francisco120 enrolled1 locationNCT06853223
Recruiting

Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation

Primary Graft DysfunctionLung transplantation
University of Pennsylvania1,150 enrolled1 locationNCT00552357
Recruiting

Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation

Primary Graft DysfunctionLung transplantation
University of Pennsylvania1,150 enrolled1 locationNCT00457847
Recruiting

EPI-STORM: Cytokine Storm in Organ Donors

Liver TransplantationKidney TransplantationGraft Dysfunction+1 more
Université de Sherbrooke105 enrolled4 locationsNCT03786991
Recruiting
Phase 1Phase 2

Chronic Lung Allograft Dysfunction MRI Study

Chronic Lung Allograft Dysfunction Lung MRI (CLAD)
Sean Fain100 enrolled1 locationNCT06406777
Recruiting

Exhaled Breath Particles in Lung Transplantation

Chronic Rejection of Lung TransplantLung Transplant RejectionPrimary Graft Dysfunction
Lund University Hospital150 enrolled1 locationNCT05375149
Recruiting

A search of novel biomarkers in detecting early allograft dysfunction afterliving donor liver transplantation

early allograft dysfunctionliving donor liver transplantation
Chang Gung Memorial Hospital120 enrolled1 locationACTRN12619000386134